Related Experiment Videos
[Clinical experience with cefodizime in bacterial infection of children]
1Department of Pediatrics, School of Medicine, University of Tokushima.
Abstract:
Clinical studies were performed on cefodizime (THR-221, CDZM), a new cephem antibiotic as described below. CDZM was administered to 13 patients in dose levels ranging from 55 to 96 mg/kg/day t.i.d. for 3-7 days (5.5 days on average). These patients included 8 with pneumonia, 2 with tonsillitis, 1 each with bronchitis, phlegmon and urinary tract infection. The overall efficacy rate was 92.3%, i.e., efficacy was excellent in 8, good in 4 and poor in 1. Bacteriological efficacy was 83.3%, i.e., 5 strains of bacteria (Streptococcus pneumoniae 1, Haemophilus influenzae 3, Haemophilus parainfluenzae 1) were eradicated and 1 was unchanged (Enterobacter cloacae, MIC greater than 100 micrograms/ml). Clinical side effect was not observed during the treatment. Laboratory abnormalities were observed in 2 cases, i.e., a slight elevation of GPT and a mild eosinophilia. The above results suggest that CDZM is a useful antibiotic for treating pediatric bacterial infections.
Insights
Cefodizime (CDZM), a novel cephem antibiotic, demonstrated high efficacy in treating pediatric bacterial infections, with a 92.3% overall success rate and no clinical side effects observed in 13 patients.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antibiotic Research
Context:
- Pediatric bacterial infections pose a significant health challenge.
- Novel antibiotic development is crucial for combating resistant pathogens.
- Cephem antibiotics are a vital class of antibacterial agents.
Purpose:
- To evaluate the clinical efficacy and safety of cefodizime (CDZM) in pediatric patients.
- To assess the bacteriological response to CDZM treatment.
- To identify potential adverse effects associated with CDZM administration.
Summary:
- Clinical studies involved 13 pediatric patients with various bacterial infections (pneumonia, tonsillitis, etc.) treated with cefodizime (CDZM) at doses of 55-96 mg/kg/day.
- An overall efficacy rate of 92.3% was observed, with excellent or good responses in 12 out of 13 patients.
- Bacteriological efficacy reached 83.3%, with eradication of key pathogens like Streptococcus pneumoniae and Haemophilus influenzae; no clinical side effects were reported, with only minor laboratory abnormalities in two cases.
Impact:
- Cefodizime (CDZM) shows promise as a safe and effective antibiotic for pediatric bacterial infections.
- The findings support the potential of CDZM as a valuable therapeutic option in pediatric infectious disease management.
- Further research may explore CDZM's role in broader pediatric populations and against a wider spectrum of resistant bacteria.